

ICUROS Newsletter

Issue 6, April 2010


Introduction

Welcome to the sixth issue of the ICUROS newsletter which will inform about the current status and recent events in the International Costs and Utilities Related to Osteoporotic Fracture Study (ICUROS). The study is endorsed by the International Osteoporosis Foundation (IOF) and is administered by i3 Innovus in Sweden (formerly European Health Economics). IOF supports ICUROS as part of the Invest in Your Bones Campaign. In addition, the study is partly funded by a consortium of sponsors, currently consisting of Amgen, Eli Lilly, Medtronic (Kyphon), Novartis, Sanofi-Aventis, Servier and Wyeth. We are grateful to all sponsors for their continuous commitment to and kind support of the study.

Patient inclusion update

We are pleased to announce that three more countries have initiated patient inclusion since the last newsletter, namely Australia, Mexico and the UK. In total, ten countries are currently including patients, the other countries being Austria, France, Italy, Lithuania, Spain, US and Russia. In the US, patient inclusion has started at three different sites but the data are omitted from the figures below.

In the generic study questionnaire, comprehensive data is collected for hip, vertebral and wrist fractures. Some countries have also chosen to enrol patients with humeral and ankle fractures. In the figures below, the total number of patients per fracture type across all countries is shown.



We encourage all investigators to keep up the good work with the patient inclusion!

Expectations for 2010

We are excited that three new countries have just initiated patient inclusion, increasing the total number of patients who will be recruited to ICUROS during the year. As the study has been going on for some time now, the number of patients completing the study is expected to increase during the year, enabling further interim analyses.

Our hopes are to also initiate patient inclusion in Germany during the year, but this is dependent on the progress of study preparations.

Preparations to start patient inclusion are also ongoing in Estonia, under the lead of Mikk Jürisson and Riina Kallikorm, but as for many other countries, the first hurdle is to secure funding.

IOF WCO - ECCEO 10

As several countries have initiated patient inclusion, 2009 was the year where follow-up data was obtained for numerous patients, making interim analyses possible. Some of these analyses will be presented at the IOF WCO – ECCEO 10 conference in Florence, Italy on May 5-8 2010.

The following ICUROS results will be presented:

1. Quality of life reduction of vertebral fractures – the difference between hospitalized and non-hospitalized patients (OC11)
2. Quality of life reduction four months after an osteoporotic fracture in France (P661)
3. Quality of life reduction one year after an osteoporotic fracture in Austria (P660)
4. Quality of life reduction one year after an osteoporotic hip fracture in Italy (P289)
5. Quality of life reduction one year after an osteoporotic fracture in Russia (P288)

The ICUROS research team will also hold an informal get-together at the congress, providing an opportunity for investigators and other interested persons to meet. Please contact Ingrid Lekander (email below) for details.

Contact information

If you would like to know more about the ICUROS project, please visit the study website at www.icuros.org or contact Ingrid Lekander at ingrid.lekander@i3innovus.com.